Loading…
Loading…
Cohen Klingenstein LLC acquired a new position in shares of Baxter International Inc. (NYSE: BAX) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 20,728 shares of the medical instruments supplier's stock, valued at approximately $497,000. Several other institutional investors and
Baxter International is rated Hold, with a $25 target price and limited 2.6% upside, reflecting muted near-term margin recovery. Revenue growth is supported by Advanced Surgery and compounding, but infusion solutions face structural headwinds, and Novum IQ LVP supply issues persist. Margins lag revenue growth; cost reductions and inventory normalization may help, but transition expenses and debt reduction remain priorities through 2027.
Omnicell (NASDAQ: OMCL - Get Free Report) and Baxter International (NYSE: BAX - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and earnings. Analyst Recommendations This is a breakdown of recent ratings
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its third-quarter 2026 financial results on Thursday, October 29, 2026, at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://events.q4inc.com/analyst/129835310?pwd=2FG2j7ZZ to pre-register for the call and receive the call information.This call is also being webcast and can be accessed through Baxter's website at www.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here is how Baxter International (BAX) and Bayer Aktiengesellschaft (BAYRY) have performed compared to their sector so far this year.
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced the release of its 2026 Connected Hospital Report, offering new insights into how hospitals across the United States are leveraging technology investments to drive clinical and operational outcomes. Based on a survey of 150 information technology (IT) and nursing leaders, the report examines how hospitals are progressing along a “connected hospital” journey by identifying four distin.
Baxter International Inc. (NYSE: BAX - Get Free Report) has earned a consensus recommendation of "Hold" from the thirteen ratings firms that are presently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and two have given a buy rating to the company.